Global Telecom Millimeter Wave (MMW) Technology Markets, 2012-2019 & 2020-2027

Globe Newswire

Liver Diseases Treatment Market to Reach $27.2 Billion by 2027

Project Details: – StrategyR – A Trademark of Global Industry Analysts, Inc. – Project Edition: 7. – Influencer Pool: 5208. – MarketGlass™ Platform – Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.New York, March 31, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report « Global Liver Diseases Treatment Industry » – https://www.reportlinker.com/p06044702/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. – Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors – Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.Mobile Access & App – Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.Complimentary Updates – for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.Bespoke Updates & Team Collaborations – Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center – clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: – Global Liver Diseases Treatment Market to Reach $27.2 Billion by 2027 – Amid the COVID-19 crisis, the global market for Liver Diseases Treatment estimated at US$13.6 Billion in the year 2020, is projected to reach a revised size of US$27.2 Billion by 2027, growing at a CAGR of 10.4% over the analysis period 2020-2027. Anti-Rejection Drugs/Immunosupressants, one of the segments analyzed in the report, is projected to record a 11.1% CAGR and reach US$4.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Chemotherapy Drugs segment is readjusted to a revised 11.6% CAGR for the next 7-year period. – The U.S. Market is Estimated at $3.7 Billion, While China is Forecast to Grow at 13.8% CAGR – The Liver Diseases Treatment market in the U.S. is estimated at US$3.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2027 trailing a CAGR of 13.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.1% and 8.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR. – Targeted therapy Segment to Record 8.2% CAGR – In the global Targeted therapy segment, USA, Canada, Japan, China and Europe will drive the 7.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1 Billion in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.9 Billion by the year 2027, while Latin America will expand at a 9.6% CAGR through the analysis period. – Select Competitors (Total 41 Featured) – AstraZeneca PLCBayer AGBristol-Myers Squibb CompanyGilead Sciences, Inc.GlaxoSmithKline PLCJohnson & Johnson Pvt., Ltd.Merck & Co., Inc.Novartis International AGPfizer, Inc.Sanofi SA Read the full report: https://www.reportlinker.com/p06044702/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Liver Diseases Treatment by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Liver Diseases Treatment by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Liver Diseases Treatment by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Anti-Rejection Drugs/Immunosupressants by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Anti-Rejection Drugs/Immunosupressants by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Anti-Rejection Drugs/Immunosupressants by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Chemotherapy Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Chemotherapy Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Chemotherapy Drugs by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Targeted therapy by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Targeted therapy by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Targeted therapy by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Vaccines by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Vaccines by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Vaccines by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Anti-Viral Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Anti-Viral Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Anti-Viral Drugs by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Iimmunoglobulins by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Iimmunoglobulins by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Iimmunoglobulins by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Corticosteroids by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Corticosteroids by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Corticosteroids by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 25: USA Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 CANADA Table 28: Canada Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 29: Canada Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: Canada 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 JAPAN Table 31: Japan Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Japan Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: Japan 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 CHINA Table 34: China Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: China Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: China 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 EUROPE Table 37: Europe Current & Future Analysis for Liver Diseases Treatment by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 38: Europe Historic Review for Liver Diseases Treatment by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: Europe 15-Year Perspective for Liver Diseases Treatment by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 40: Europe Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: Europe Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: Europe 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 FRANCE Table 43: France Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: France Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: France 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 GERMANY Table 46: Germany Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: Germany Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: Germany 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 ITALY Table 49: Italy Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 50: Italy Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Italy 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 52: UK Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: UK Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: UK 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 SPAIN Table 55: Spain Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: Spain Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: Spain 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 RUSSIA Table 58: Russia Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: Russia Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: Russia 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 REST OF EUROPE Table 61: Rest of Europe Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: Rest of Europe Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: Rest of Europe 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 64: Asia-Pacific Current & Future Analysis for Liver Diseases Treatment by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 65: Asia-Pacific Historic Review for Liver Diseases Treatment by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Asia-Pacific 15-Year Perspective for Liver Diseases Treatment by Geographic Region – Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 67: Asia-Pacific Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Asia-Pacific Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Asia-Pacific 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 AUSTRALIA Table 70: Australia Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: Australia Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: Australia 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 INDIA Table 73: India Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: India Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: India 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 SOUTH KOREA Table 76: South Korea Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: South Korea Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: South Korea 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 REST OF ASIA-PACIFIC Table 79: Rest of Asia-Pacific Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: Rest of Asia-Pacific Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: Rest of Asia-Pacific 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 LATIN AMERICA Table 82: Latin America Current & Future Analysis for Liver Diseases Treatment by Geographic Region – Argentina, Brazil, Mexico and Rest of Latin America Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 83: Latin America Historic Review for Liver Diseases Treatment by Geographic Region – Argentina, Brazil, Mexico and Rest of Latin America Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Latin America 15-Year Perspective for Liver Diseases Treatment by Geographic Region – Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 Table 85: Latin America Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Latin America Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Latin America 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 ARGENTINA Table 88: Argentina Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Argentina Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Argentina 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 BRAZIL Table 91: Brazil Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Brazil Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Brazil 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 MEXICO Table 94: Mexico Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 95: Mexico Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Mexico 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 REST OF LATIN AMERICA Table 97: Rest of Latin America Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Rest of Latin America Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Rest of Latin America 15-Year Perspective for Liver Diseases Treatment by Treatment Type – Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2012, 2020 & 2027 MIDDLE EAST Table 100: Middle East Current & Future Analysis for Liver Diseases Treatment by Geographic Region – Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 101: Middle East Historic Review for Liver Diseases Treatment by Geographic Region – Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Middle East 15-Year Perspective for Liver Diseases Treatment by Geographic Region – Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027 Table 103: Middle East Current & Future Analysis for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Middle East Historic Review for Liver Diseases Treatment by Treatment Type – Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06044702/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001